ClinicalTrials.gg
Enrolling by invitationNCT06907303RNA-EndoDxUpdated Nov 12, 2026

RNA Assays for Endometriosis Detection and Diagnosis

An observational study in Endometriosis, sponsored by Wren Laboratories LLC. Enrolling by invitation at 3 sites in 2 countries. Open to female participants aged 20 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Wren Laboratories LLC · Observational

How we know

Updated Nov 12, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
400
Ages
20 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 169 studies in Endometriosis with a site in United States — 38 open to participants now, 48 under way, 5 of them phase 3. Endometriosis · United States.

Planned enrollment
14th of 38
400 · median 187
Started
2024
with 10 others
Observational
38 of 169
14 open now
Primary completion
2028-08
later than 33 of 47 live
Registered
150th of 169
by date

Among the 169 studies in Endometriosis with a site in United States, this one is the 14th largest by planned enrollment of the 38 observational ones that give a count, is one of 11 that started in 2024, is one of 38 observational ones, reaches primary completion later than 33 of the 47 other live ones, and was the 150th registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

38 of the 169 studies in Endometriosis with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 20 Years to 35 Years · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 169 studies in Endometriosis with a site in United States, or all of them as a file.
02

Study summary

Endometriosis is a common disease that affects up to 10% of women of reproductive age. Diagnosis, however, is typically delayed (up to 12 years) and is usually made after surgery. A key unmet need therefore is an accurate biomarker that can be used to detect the disease early. This study is a prospective trial to identify candidate mRNA-markers which can be used to aid in the diagnosis of this disease. It is a discovery/validation study that will identify and confirm a gene expression panel that is specific for endometriosis and provides a non-invasive tool for future use.

Read the detailed description

Endometriosis is a common disease that affects up to 10% of women of reproductive age. Diagnosis, however, is typically delayed (up to 12 years) and is typically made after surgery. A key unmet need therefore is an accurate, non-invasive biomarker that can be used to detect the disease early.

We hypothesize that endometriosis-related circulating gene expression can be identified using transcriptomic and bioinformatics approaches and used to construct an accurate diagnostic tool for this condition.

The primary objective is to develop a gene signature that detects endometriosis. The hypothesis is that this disease is characterized by a set of genes that characterize endometriosis tumor biology.

The aim is to detect over-expressed genes (elevated mRNA expression) in endometriosis tissue. The goal is to identify 10-25 biomarker genes that are highly expressed to form a candidate biomarker panel.

Highly expressed genes will be determined against samples collected from age/menstrual stage matched controls. A bio-informatics approach will be used to identify these over-expressed genes. This form the basis of a potential diagnostic panel.

Per PICOT criteria:

  • The target patient population are women aged 20-35 years with a pathological diagnosis of endometriosis.
  • The intervention is sample collection at the time of diagnosis (tissue, blood, saliva)
  • The comparison group are normo-ovulatory subjects (age 20-25 years) undergoing surgery for benign cervical lesions.
  • The outcome is a gene signature that is associated with endometriosis.
  • The follow-up time is one year.

The secondary objective is to test the diagnostic utility of the 10-25 gene panel. This will be undertaken using the retrospectively collected samples.

  • Each of the highly expressed genes will be measured and quantified using an RT-PCR approach.
  • Genes that are statistically over-expressed in the endometriosis samples will be selected for a PCR panel.
  • The expression of genes in the PCR panel will be scored.
  • Low scores will be related to "control" and higher scores to "endometriosis".
  • The scores will be formally evaluated as a diagnostic (area under the curve analysis, accuracy, sensitivity and specificity metrics).
  • A specific comparison will be made between the endometriosis cohort and the control cohort.
  • The metrics for a successful assay are:

    • Accuracy >80%
    • Sensitivity >90%
    • Specificity >85%
    • AUC >0.8
03

Conditions studied

  • Endometriosis

Keywords

  • Endometriosis
  • Diagnosis
  • Gene Expression
  • PCR
04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

Women with high suspicion of endometriosis and women undergoing surgery for benign cervical disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For the endometriosis cohort

  • a history of infertility more than 1 year
  • age 20-35 years
  • normal liver and kidney function, without gynaecological and other systemic disease

Inclusion criteria for controls include normo-ovulatory history, aged between 20-35 years, who exhibit normal liver and kidney function, and do not have any systemic diseases including disease.

-

Exclusion criteria

Exclusion Criteria:

For the endometriosis cohort

  • polycystic ovary syndrome, hyperprolactinemia
  • severe cardiovascular system, liver, kidney, and hematopoietic system disease
  • disease
  • uterine fibroids, endometritis, non-vegetative ovarian cysts, ovarian , and internal genital tuberculosis

Exclusion criteria for the controls includes gynaecological malignancies and genital tuberculosis.

-

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Endometriosis

    Women with suspected endometriosis undergoing laparoscopy to provide tissue for pathological diagnosis of the disease.

    Diagnostic Test: EndoDx

  • Control

    Women undergoing surgery for benign cervical disease.

    Diagnostic Test: EndoDx

Interventions

  • Diagnostic testEndoDx

    PCR assay for Endometriosis diagnosis

06

What researchers measure

Primary outcomes

  1. Develop a gene signature that detects endometriosis

    Gene expression levels in samples from endometriosis subjects and controls

    Time frame: 12-18 months

Secondary outcomes

  1. Assess the diagnostic utility of the gene signature to differentiate between endometriosis and controls

    Algorithmic analysed normalized gene expression levels in samples from endometriosis subjects and controls

    Time frame: 6 months

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Aug 2028, 55 months after the start.

Of 185 observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 55 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Aug 2025 → Aug 2028 and completion Dec 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 2, 2025
StartActual
Jan 1, 2024
Primary completionEst.
Aug 31, 2028was Aug 2025
CompletionEst.
Dec 31, 2028was Dec 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Charlotte Johnson Hollfelder Center for Women's Health · Farmington, United States
Nov 12, 2026
Primary completion
Aug 31, 2025→Aug 31, 2028
Nov 12, 2026
Study completion
Dec 31, 2026→Dec 31, 2028
Nov 12, 2026
Sponsor
Collaborators added: UConn School of Medicine
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    1 site added
    Show site
    • Charlotte Johnson Hollfelder Center for Women's Health · Farmington, United States
    Primary completion Aug 31, 2025→Aug 31, 2028
    Study completion Dec 31, 2026→Dec 31, 2028
    Sponsor Collaborators added: UConn School of Medicine
    + 2 other changes: verification date and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06907303
Lead sponsor
Wren Laboratories LLC
Collaborators
University of Cape Town, UConn School of Medicine
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
Jan 1, 2024
Primary completion
Aug 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion